Aim: We designed this study to evaluate the prevalence of comorbidities, their monitoring states and association with treatment medication in Korean rheumatoid arthritis (RA) patients compared with patients from other countries.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects synovial joints. In addition to articular pain and functional limitations, patients with RA can suffer from comorbidities.
1 Some comorbidities, such as cardiovascular (CV) diseases, osteoporosis, infection and several types of cancer, are more frequently found in RA patients than in the general population; these conditions are associated with RA itself or with the medications used to treat it. [2] [3] [4] [5] [6] We designed this study to evaluate the prevalence of comorbidities and their monitoring states in Korean RA patients compared with patients from other countries using a database provided by an international, crosssectional study evaluating comorbidities of RA (COMORA).
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MATERIALS AND METHODS
This cross-sectional, observational, multicenter, international study is an ancillary study of COMORA study and used already analyzed data from COMORA database. We analyzed the demographics, disease characteristics, comorbidities and health monitoring status of 1050 RA patients from 11 South Korean centers (Korean cohort) and compared them with the 3520 patients from the other 16 countries using the COMORA database (international cohort included Argentina, Austria, Egypt, France, Germany, Hungary, Italy, Japan, Morocco, Netherlands, Spain, Taiwan, United Kingdom, Uruguay, United States, Venezuela). The protocol was approved by the Seoul National University College of Medicine-Seoul National University Hospital Institutional Review Board (IRB), Catholic University of Korea St. Mary's Hospital IRB, Samsung Medical Center IRB, Inha University Hospital IRB, Hallym University Sacred Heart Hospital IRB, Hanyang University Medical Center IRB, Gachon University Gil Medical Center IRB, Pusan National University Hospital IRB, Severance Hospital IRB and Eulji University Hospital IRB and the study was performed in accordance with the principles of the 1964 Declaration of Helsinki. All persons gave their informed consent prior to their inclusion in the study.
Sample size
The original COMORA study (n = 3920) included 400 patients randomly selected from 1050 Korean patients. In this ancillary study, all 1050 Korean patients were analyzed and compared with the 3520 patients from the other 16 countries (3920 COMORA cohort minus 400 Koreans). Patient composition in international and Korean cohorts is summarized in Figure 1 .
Data collected
A protocol specifically created for COMORA study was used to collect four categories of data, which were patient's demographic characteristics, comorbidities, coexisting risk factors and compliance with current national recommendations regarding management of these comorbidities. 7 Patient's demographic characteristics included age, gender, body mass index, smoking status, alcohol intake, marital status, socioeconomic status and highest level of education completed. In addition, disease activity was assessed utilizing the disease activity score using 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) 8, 9 and medications used to treat RA were recorded.
Comorbidities consisted of ischemic CV disease (myocardial infarction, stroke), solid cancers (in colon, skin, lung, breast and uterus for women, prostate for men) and lymphoma, gastrointestinal diseases (diverticulitis, ulcers), infections (hepatitis), lung disease (chronic obstructive pulmonary disease [COPD], asthma) and psychiatric disorders (depression).
Risk factors for CV diseases consisted of hypertension, diabetes, dyslipidemia, family history of myocardial infarction in first degree relatives or sudden death in first degree relatives prior to age 55 in male relatives and prior to age 65 in female relatives. Hypertension was defined as: (i) those ever diagnosed as having hypertension and receiving anti-hypertensive therapy; or (ii) systolic pressure > 140 mmHg or diastolic pressure > 80 mmHg; or (iii) > 130 mmHg and 70 mmHg in the setting of concomitant diabetes mellitus. 10 Diabetes was defined as: (i) those ever diagnosed as diabetes and receiving therapy; or (ii) random blood glucose level > 1.26 g/L.
11 Dyslipidemia was defined as: (i) those ever diagnosed as having dyslipidemia and receiving anti-dyslipidemia therapy; or (ii) low-density lipoprotein cholesterol above the targeted value defined with regard to the number of concomitant additional CV risk factors. 12 Compliance with current national recommendations regarding management of these comorbidities was also evaluated. For example, patients older than 50 years were considered to be managed optimally if they were receiving an antiplatelet agent in the setting of a past thrombotic CV event or if their Framingham risk score 13 was calculated to be 20% or more after being adjusted for RA (multiplied by a factor of 1.5).
14 Risk factors for infectious diseases consisted of yearly dentist visit and vaccination status. A patient was considered to be monitored optimally for infectious diseases if he or she had: (i) a dental examination within the previous year; (ii) an influenza vaccination within the previous year; and (iii) a pneumococcal vaccination within the previous 5 years. 15 Risk factors for cancers consisted of family history of prostate, breast or colon cancer, adenomatous polyposis and/or personal history of inflammatory bowel disease (for colon cancer) and history of numerous nevi (or skin cancers). A patient was considered to be monitored optimally for cancer if age-and sex-appropriate cancer screening recommendations for the general population were followed.
A patient was considered to have been screened optimally for osteoporosis if at least one bone densitometry study had been performed after the onset of RA and if he or she was taking vitamin D supplementation at the time of the study visit. 16 For each patient, information was collected by a study investigator during a face-to-face interview at a dedicated study visit and through review of the medical record.
Statistical analyses
Statistical analyses were performed using SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) and SAS version 9.1.3 (SAS Institute, Inc., Cary, NC, USA). Graphics were generated in R version 3.0.1 (http://www.r-project.org/). All data are expressed as proportion (%) or mean (AE SD) as appropriate. Mean values of continuous variables were compared using Student's t-test and proportions were compared using the chi-square test. Logit models for binary data were used to calculate odds ratios. A P-value < 0.05 was considered statistically significant.
RESULTS
Baseline demographics and disease characteristics of RA patients
The baseline demographics and disease characteristics of RA patients are summarized in Table 1 . Korean RA patients were less likely to be smokers or overweight and more likely to be married compared to the international cohort. They tended to have shorter disease duration and lower disease activity compared to the 
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International Journal of Rheumatic Diseases 2018; 21: 1414-1422 international cohort. The use of methotrexate was similar, glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) were more often and biologic diseasemodifying antirheumatic drugs (DMARDs) were less often used in the Korean compared to the international cohort.
Prevalence of comorbidities
Prevalence of myocardial infarction, stroke, hepatitis B and gastrointestinal ulcers in the Korean cohort were not significantly different from the prevalence in the international cohort. Prevalence of basocellular skin cancer was significantly lower in Koreans but overall prevalence of solid cancers excluding basocellular skin cancer was not significantly different between the Korean and international cohorts. Prevalence of hepatitis C, COPD, asthma and depression were significantly lower and prevalence of surgery for diverticulitis was higher in Koreans compared to the international cohort. Analysis of comorbidities is shown in Table 2 .
Prevalence of risk factors for comorbidities
Smoking, family history of CV disease and hyperlipidemia were less frequent in Korean RA patients while diabetes was more frequent. The proportion of patients with Framingham score > 20% was significantly lower in Koreans compared to the international cohort.
The prevalence of family history of breast cancer and colon cancer were lower in Koreans. In addition, there was no patient with a history of inflammatory bowel disease or large numbers of skin nevi (> 40) in the Korean cohort (Table 3) .
Management of comorbidities
Annual evaluations of cardiovascular risk, including measurements of blood pressure, serum creatinine, glucose and cholesterol were performed less in Koreans. More patients were receiving optimal antiplatelet therapy in Korea compared to the international cohort. Of the 52 patients who had a prior myocardial infarction or stroke, 34 (65.4%) were currently receiving an antithrombotic drug and 18 (34.6%) were not. Among the other 998 patients who had no history of myocardial infarction or stroke, 63 patients were good candidates for prophylactic antithrombotic drug treatment because they were over the age of 50 and had a calculated Framingham risk score above 20%; however, of these, 51 (81.0%) patients were not receiving any antithrombotic agents. Thus, a total of 69 patients (6.6%) enrolled in this study should have been treated with antithrombotic drug prophylaxis to prevent cardiovascular events but were not being managed optimally and this prevalence is significantly less than in the international cohort.
Of Korean RA patients, 36.5% received an influenza vaccination during the year before the study visit, although the international prevalence was lower (24.5%, P < 0.0001). A pneumococcal vaccination had been given to only 11.1% of Korean patients within 5 years of the study visit, which is even less than in the international cohort (17.9%, P < 0.0001). Both an influenza and a pneumococcal vaccination were given according to current recommendations in only 102 (9.7%) of patients.
Prostate and skin cancer screening were less frequently performed and lung and breast cancer monitoring were more frequent in Korean RA patients. Bone densitometry was more frequently done but vitamin D supplements were taken less in Korea compared to the international cohort (Table 4) . 
DISCUSSION
This study reveals differences in the prevalence of comorbidities and risk factor monitoring status between RA patients in Korea and in 16 other countries. Several distinct characteristics of Korean patients were shown in this report, such as lower frequency of smoking or obesity and high frequency of married patients. RA activity was lower and usage of biologic DMARDs was significantly less. This lower biologic usage would be co-joined with higher prevalence of steroids (73.9%) and NSAIDs use (78.6%).
There had been a prospective RA cohort in South Korea, the KORean Observational Study Network for Arthritis (KORONA), which was composed of 4721 patients from 23 institutions. Patients in KORONA were similar to the Korean cohort in this study in that there was a low prevalence of current smokers (8.01%) and biologics users (5.78%) and a high prevalence of NSAID users (81.03%) and steroid users (73.99%). 17 KORONA also collected some data about the presence of comorbidities via patient interviews, such as hypertension and diabetes, but did not evaluate the risk factors for comorbidities or monitoring status of the comorbidities. Therefore, to the best of our knowledge, this is the first large-scale cohort study to address comorbidities in Korean patients with RA.
In this study, we found that vaccination for the prevention of infectious diseases or monitoring and primary prevention for CV disease are not conducted fully in accordance with current recommendations. Influenza and pneumococcal vaccination is provided free to patients over 65 years in Korea. However, patients with RA are in need of annual influenza vaccination and pneumococcal vaccination even when they are under 65 years and rheumatologists in Korea need to be aware of their patients' vaccination status and to assure their patients receive appropriate prevention.
In addition, the prevalence of CV morbidity was similar between Korean and international cohorts even though the prevalence of CV risk factors, especially the proportion of patients with Framingham score > 20% was significantly lower in the Korean cohort. We cannot explain the exact cause of this inconsistency in our results. Further studies investigating unknown risk factors or genetic contribution may be needed to explain this relatively higher prevalence of CV morbidity compared to the low prevalence of known risk factors. In fact, annual evaluations of cardiovascular risk, including measurements of blood pressure, serum creatinine, glucose and cholesterol were less frequently performed in the Korean cohort and it can provide a basis for the suggestion that Korean rheumatologists should pay more attention to risk monitoring and primary prevention for CV disease.
Lung cancer monitoring with chest X-ray and breast cancer monitoring with mammography, which are included in the national health screening program in Korea for people over 40 years of age, 18 were performed at optimal levels in Korean patients.
Skin cancer screening was performed significantly less frequently and prevalence of skin cancer was also significantly lower in the Korean cohort. There was only one case of malignant melanoma and no case of non-melanoma skin cancer in the Korean cohort. There are possibilities of ignored cases of non-melanoma skin cancer in Korea due to lack of screening. However, it is also true that the prevalence of skin cancer is quite low in the general Korean population and this may contribute to the low skin cancer screening rate in Korea. The age-standardized incidence rate (ASR) of malignant melanoma in the general Korean population was 1.0/100, 000 and ASR of non-melanoma skin cancer was 5.0/100 000 in 2013. 19 In comparison, ASR of malignant melanoma was 16.8/ 100, 000 in men and 12.6/100, 000 in women among the general population of the USA and 13.7/ 100, 000 in men and 15.6/100, 000 in women among the general population of the UK in 2012. 20 In the statistics of the International Agency for Research on Cancer, age-world-standardized incidence rate of malignant melanoma is significantly lower in east-Asia compared to the rest of the world. 21 Even in the statistics of the Centers of Disease Control and Prevention within US residents, skin cancer rates were different by race and ethnicity and Asian/Pacific Islanders had significantly lower incidence compared to all races. 22 Prevalence of skin cancer is low in the general population of Korea but the incidence is continuously increasing. 23 Therefore, it is better for Korean rheumatologists to pay attention to the monitoring of skin cancer.
Prostate cancer monitoring was also less often performed in Korean patients, suggesting that more attention to prostate cancer monitoring is warranted.
There are several limitations to this study. First, the Korean cohort consisted of patients from 11 academic hospitals across South Korea. Although they were regionally well distributed, all the centers were tertiary hospitals and the patients in these centers may not be representative of typical RA patients in Korea. The same weakness also exists in the international cohort and COMORA authors reported a potential weakness of inability to guarantee that all patients studied in the COMORA cohort (3920 patients) were fully representative of RA patients in the participating countries. 7 Second, although this is the first large-scale cohort study concerning comorbidities in Korean RA patients, a cohort of 1050 patients is not large enough to analyze the prevalence of rare comorbidities such as malignancies. The prevalence of several solid cancers such as prostate, colon and skin cancer was too low to obtain a statistically significant odds ratio. Also, some of the risk factors of malignancy such as a history of inflammatory bowel disease or an unusually large number of skin nevi (> 40) did not exist in the Korean RA cohort. Third, monitoring and prevention of osteoporosis and vaccination states were accessed but actual prevalence of osteoporosis, spine and hip fracture, tuberculosis and pneumonia were not included in the study. Also, endocrinopathies such as thyroid disease and metabolic syndrome represent relevant comorbidities but were not included in the study.
However, to the best of our knowledge, this is the first large-scale cohort study to address comorbidities with risk factors and monitoring status of RA patients in Korea. The current findings on the prevalence of comorbidities and risk factors in Korea will be helpful to rheumatologists in other Asian and non-Asian countries with similar situations.
In summary, the prevalence of CV morbidity was similar between patients in Korea and those in other countries, although the prevalence of CV risk factors is significantly low in Korea. Prostate cancer screening was less frequently performed compared to other countries and < 10% of Korean RA patients were given both influenza and a pneumococcal vaccination according to current recommendations. Bone densitometry was more frequently done but vitamin D supplements were taken less in Korea compared to the international cohort. This suggests that rheumatologists in Korea need to pay more attention to yearly CV risk monitoring, in addition to the screening of malignancy, vitamin D supplements and vaccination of RA patients against infectious diseases.
